TCGA-UF-A7JA-01A-12R-A34R-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- female
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CN-A49A-01A-11R-A24H-07 | — | — | 0.908 |
| 2 | TCGA-21-5782-01A-01R-1635-07 | — | cohortSC | 0.902 |
| 3 | SRR650204 | — | — | 0.896 |
| 4 | TCGA-CV-7424-01A-11R-2081-07 | — | — | 0.889 |
| 5 | SRR12202488 | — | — | 0.887 |
| 6 | SRR12696774 | — | — | 0.884 |
| 7 | e3d71c3f-4e56-45fa-be88-2cf444b70a5c | — | — | 0.883 |
| 8 | SRR1321183 | GTEX | — | 0.883 |
| 9 | MNG560 | — | — | 0.880 |
| 10 | SRR1334717 | GTEX | — | 0.871 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 7 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.320 | Cobimetinib | — uncovered |
| ANGIOGENESIS | 0.180 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_DN | 0.140 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.090 | Inavolisib | — uncovered |
| HYPOXIA | 0.040 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.040 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.010 | Inavolisib | — uncovered |